Up­dat­ed: FDA says it has no plans for Is­rael-based of­fice

Last year
FDA+

Biden ad­min­is­tra­tion to use De­fense Pro­duc­tion Act to tack­le drug short­ages

Last year
Pharma
FDA+

J&J’s new part­ner­ship with Elek­trofi; Enyo rais­es €39M; Ar­row­head­'s $450M of­fer­ing

Last year
News Briefing

Boehringer In­gel­heim once again turns to RNAi for new MASH ther­a­pies

Last year
Deals

Agios’ oral drug se­cures PhI­II suc­cess in trans­fu­sion-in­de­pen­dent tha­lassemia pa­tients

Last year
R&D

Roger Perl­mut­ter lights up the bi­o­log­i­cal dark, build­ing a new phar­ma force in Eikon and its su­per­pow­ered mi­cro­scopes

Last year
Startups
R&D

No­vo Nordisk eyes fur­ther Eu­ro­pean man­u­fac­tur­ing ex­pan­sion as it buys land in Ire­land

Last year
Manufacturing

In­vivyd re­quests emer­gency use au­tho­riza­tion for Covid-19 pre­ven­tive an­ti­body among im­muno­com­pro­mised

Last year
FDA+
Coronavirus

Gold­man Sachs clos­es $650M life sci­ences fund to bankroll in­dus­try’s ‘gold­en era’

Last year
Financing
Startups

Roche lines up RNA pact with Remix Ther­a­peu­tics, which al­so raised an­oth­er $60M

Last year
Financing
Startups

NGM Bio sub­ject of take-pri­vate bid by in­sti­tu­tion­al in­vestor The Col­umn Group

Last year
Deals
R&D

Blad­der can­cer drug­mak­er CG On­col­o­gy files for IPO as biotech mar­ket shows signs of a re­bound

Last year
Financing

Yale Law School's free speech group says Boehringer's IRA ar­gu­ment is 'fun­da­men­tal­ly flawed'

Last year
Pharma
Law

Court grants FTC in­junc­tion over IQVI­A's deal with Pro­pel Me­dia and Deep­In­tent

Last year
Pharma
Marketing

Bey­for­tus ap­proved in Chi­na to pro­tect in­fants from RSV; Il­lu­mi­na in­vestor files class ac­tion suit

Last year
Pharma

Cor­cept los­es patent fight with Te­va over Cush­ing's syn­drome drug

Last year
Pharma
Law

Long­board stock soars on heels of pos­i­tive topline da­ta for seizure med­ica­tion

Last year
R&D
Pharma

Omeza warned over poor man­u­fac­tur­ing con­di­tions; MiMedx in FDA talks over Ax­iofill re­clas­si­fi­ca­tion

Last year
Pharma
Manufacturing

Mar­ket­ingRx roundup: Gilead, Pfiz­er spon­sor di­vas’ ben­e­fit con­cert; Am­gen joins Rose Pa­rade

Last year
Pharma
Marketing

Anavex’s ex­per­i­men­tal drug fails Rett syn­drome study, stock falls

Last year
R&D

As­traZeneca's $40M deal with Al­lo­ri­on; Apol­lo rais­es $33M; Xo­ma's stock buy­back

Last year
News Briefing

Brand drug nam­ing faces chal­lenges in emerg­ing cat­e­gories, ex­pert says

Last year
Pharma
Marketing

Roche inks $50M ADC pact with Chi­nese biotech as field­'s flur­ry spills over in­to 2024

Last year
Deals
China

Sanofi, Re­gen­eron and Ab­b­Vie lead phar­ma TV ad­ver­tis­ers in boom­ing 2023

Last year
Pharma
Marketing
First page Previous page 224225226227228229230 Next page Last page
A service from the Financial Times